GROWTH INHIBITORY EFFECT OF BESTATIN ON CHORIOCARCINOMA CELL-LINES INVITRO

被引:23
作者
INO, K
GOTO, S
KOSAKI, A
NOMURA, S
ASADA, E
MISAWA, T
FURUHASHI, Y
MIZUTANI, S
TOMODA, Y
机构
[1] Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Showa-ku, Nagoya, 466
关键词
AMINOPEPTIDASE-INHIBITOR; BESTATIN; CHORIOCARCINOMA; SUCCINATE DEHYDROGENASE INHIBITION TEST;
D O I
10.1007/BF02221328
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bestatin, one of the biological response modifiers (BRMs), is an inhibitor of aminopeptidase B (AP-B), leucine aminopeptidase (LAP) and aminopeptidase M (AP-M). In this report, we investigated the direct effect of bestatin on the growth of cancer cells in vitro using established four choriocarcinoma cell lines. In vitro chemosensitivity was evaluated by the succinate dehydrogenase inhibition (SDI) test. Bestatin showed the growth-inhibitory effect on all the choriocarcinoma cell lines dose-dependently, especially on NaUCC-4 cells. Both an isomer of bestatin with no inhibitory activity against aminopeptidases, (2R, 3S)-AHPA-(R)-Leu, and another isomer with stronger inhibitory activity against AP-B than bestatin, (2S, 3S)-AHPA-(R)-Leu, did not show growth inhibition on NaUCC-4 cells. So it is suggested that one of the possible mechanisms responsible for the direct action of bestatin on the choriocarcinoma cells may be related to the inhibition of activity of LAP or AP-M rather than that of AP-B. Furthermore, cytotoxicity of actinomycin D on the choriocarcinoma cells was significantly enhanced by combination with bestatin. These results suggest that bestatin has not only an indirect host-mediated anti-tumor activity, but also a direct growth-inhibitory effect on some kinds of cancer cell lines.
引用
收藏
页码:351 / 357
页数:7
相关论文
共 27 条
  • [1] ABE F, 1984, GANN, V75, P89
  • [2] EFFECTS OF BESTATIN ON INTRAUTERINE GROWTH OF RAT FETUSES
    FURUHASHI, M
    MIZUTANI, S
    KURAUCHI, O
    KASUGAI, M
    TOMODA, Y
    [J]. HORMONE AND METABOLIC RESEARCH, 1989, 21 (07) : 366 - 368
  • [3] GOTO S, 1988, CANCER, V62, P873, DOI 10.1002/1097-0142(19880901)62:5<873::AID-CNCR2820620504>3.0.CO
  • [4] 2-K
  • [5] A CONTROLLED TRIAL OF BESTATIN IN HYDATIDIFORM MOLE
    HO, PC
    WONG, LC
    LAWTON, JWM
    MA, HK
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 31 (03) : 187 - 190
  • [6] IDOTA C, 1990, Journal of Japan Society for Cancer Therapy, V25, P85
  • [7] EFFECT OF BESTATIN ON MOUSE IMMUNE-SYSTEM AND EXPERIMENTAL MURINE TUMORS
    ISHIZUKA, M
    MASUDA, T
    KANBAYASHI, N
    FUKASAWA, S
    TAKEUCHI, T
    AOYAGI, T
    UMEZAWA, H
    [J]. JOURNAL OF ANTIBIOTICS, 1980, 33 (06) : 642 - 652
  • [8] ISHIZUKA M, 1989, GANN MONOGRAPH CANCE, V36, P147
  • [9] ENHANCEMENT OF CYTO-TOXICITY OF CISPLATIN INVITRO BY RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR AND OR RECOMBINANT HUMAN INTERFERON-ALPHA, INTERFERON-BETA AND INTERFERON-GAMMA
    KIM, CM
    HONG, WS
    LEE, JO
    KANG, TW
    KIM, YW
    SONG, JK
    YUN, TK
    KIM, CY
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (09): : 904 - 909
  • [10] IDENTIFICATION AND PROPERTIES OF THE CELL-MEMBRANE BOUND LEUCINE AMINOPEPTIDASE INTERACTING WITH THE POTENTIAL IMMUNOSTIMULANT AND CHEMOTHERAPEUTIC AGENT BESTATIN
    LEYHAUSEN, G
    SCHUSTER, DK
    VAITH, P
    ZAHN, RK
    UMEZAWA, H
    FALKE, D
    MULLER, WEG
    [J]. BIOCHEMICAL PHARMACOLOGY, 1983, 32 (06) : 1051 - 1057